Literature DB >> 8385584

Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis.

I C Chikanza1, P Roux-Lombard, J M Dayer, G S Panayi.   

Abstract

Tumour necrosis factor-alpha (TNF-alpha) is involved in diverse biological processes including immune and inflammatory reactions and the response to surgical stress. Two soluble TNF receptor protein fragments, TNF-sR55 (from the p55 kD TNF receptor) and TNF-sR75 (from the p75 kD TNF receptor), are released by cells during inflammation and may modulate the e effects of TNF-alpha. We have studied the kinetics of secretion of TNF-alpha, TNF-sR55 and TNF-sR75 in the sera of patients with rheumatoid arthritis (RA) and control subjects with osteoarthritis (OA) or chronic osteomyelitis (OM) before and after major surgery. Significantly higher pre-operative levels of TNF-sR55 and TNF-sR75 were found in RA and OM as compared with OA (P < 0.02). Following surgery, TNF-sR55 increased within 24 h in RA, OM and OA (P < 0.05), whereas TNF-sR75 increased significantly only in OM and OA patients (P < 0.05). By contrast, no TNF-alpha was detectable before and after surgery in any of the subjects, but this may have been due to impaired detection (by ELISA) of TNF-alpha when it is bound to TNF-sR. These findings suggest that TNF-sR55 and TNF-sR75 may be further markers of the host's reaction to inflammatory insults. They may also play a role in modulating the immune and inflammatory reactions by inhibiting the systemic effects of TNF-alpha.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8385584      PMCID: PMC1554888          DOI: 10.1111/j.1365-2249.1993.tb05941.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

2.  Tumor necrosis factor inhibits the development of viral meningitis or induces rapid death depending on the severity of inflammation at time of administration.

Authors:  P C Doherty; J E Allan; I A Clark
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

3.  Molecular cloning and expression of a receptor for human tumor necrosis factor.

Authors:  T J Schall; M Lewis; K J Koller; A Lee; G C Rice; G H Wong; T Gatanaga; G A Granger; R Lentz; H Raab
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

4.  Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors.

Authors:  H Engelmann; D Novick; D Wallach
Journal:  J Biol Chem       Date:  1990-01-25       Impact factor: 5.157

5.  Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies.

Authors:  M Brockhaus; H J Schoenfeld; E J Schlaeger; W Hunziker; W Lesslauer; H Loetscher
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

6.  Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor.

Authors:  H Loetscher; Y C Pan; H W Lahm; R Gentz; M Brockhaus; H Tabuchi; W Lesslauer
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

7.  A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins.

Authors:  C A Smith; T Davis; D Anderson; L Solam; M P Beckmann; R Jerzy; S K Dower; D Cosman; R G Goodwin
Journal:  Science       Date:  1990-05-25       Impact factor: 47.728

8.  A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity.

Authors:  H Engelmann; D Aderka; M Rubinstein; D Rotman; D Wallach
Journal:  J Biol Chem       Date:  1989-07-15       Impact factor: 5.157

9.  Isolation and characterization of a tumor necrosis factor binding protein from urine.

Authors:  I Olsson; M Lantz; E Nilsson; C Peetre; H Thysell; A Grubb; G Adolf
Journal:  Eur J Haematol       Date:  1989-03       Impact factor: 2.997

10.  A human inhibitor of tumor necrosis factor alpha.

Authors:  P Seckinger; S Isaaz; J M Dayer
Journal:  J Exp Med       Date:  1988-04-01       Impact factor: 14.307

View more
  7 in total

1.  Soluble TNF receptors as prognostic factors for mortality.

Authors:  R W Parks; K R Gardiner; M I Halliday; B J Rowlands
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

2.  Local expression of tumor necrosis factor alpha in an experimental model of acute osteomyelitis in rats.

Authors:  A J Littlewood-Evans; M R Hattenberger; C Lüscher; A Pataki; O Zak; T O'Reilly
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

3.  Significance of systemic endotoxaemia in inflammatory bowel disease.

Authors:  K R Gardiner; M I Halliday; G R Barclay; L Milne; D Brown; S Stephens; R J Maxwell; B J Rowlands
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

4.  Soluble tumour necrosis factor receptors (sTNF-R) and HIV infection: correlation to CD8+ lymphocytes.

Authors:  A Kalinkovich; G Livshits; H Engelmann; N Harpaz; R Burstein; M Kaminsky; D Wallach; Z Bentwich
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

5.  Circulating tumor necrosis factor alpha (TNF), soluble TNF receptors, and interleukin-6 in human subacute bacterial endocarditis.

Authors:  W V Kern; A Engel; S Schieffer; O Prümmer; P Kern
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

6.  Neutrophil expression of tumour necrosis factor receptors (TNF-R) and of activation markers (CD11b, CD43, CD63) in rheumatoid arthritis.

Authors:  S Lopez; L Halbwachs-Mecarelli; P Ravaud; G Bessou; M Dougados; F Porteu
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

7.  Plasma cytokine profiles in HIV-1 infected patients developing neuropathic symptoms shortly after commencing antiretroviral therapy: a case-control study.

Authors:  Johan J Van der Watt; Katalin A Wilkinson; Robert J Wilkinson; Jeannine M Heckmann
Journal:  BMC Infect Dis       Date:  2014-02-10       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.